Cuba reported today 592 new COVID-19 cases, 2 deaths, and 786 medical discharges.

The president of Fiji, Jioji Konusi Konrote, expressed his gratitude to Cuba for its contribution to the training of health professionals by welcoming Cuban ambassador Carlos Manuel Rojas, who concludes his mission to that South Pacific country.

As of Nov. 1, 9,963,447 people have received at least one dose of one of the Cuban anti-COVID-19 vaccines Soberana 02, Soberana Plus and Abdala, the Cuban Ministry of Public Health (MINSAP by its Spanish acronym) reported today.

Cuba tested a total of 20,201 samples for COVID 19, with 567 positive. The country accumulates 10,579,169 samples and 953,750 positive.

As of October 31, 9, 939,797 people had received at least one dose of one of the Cuban anti-COVID-19 vaccines Soberana 02, Soberana Plus and Abdala, the Cuban ministry of public health ( MINSAP by its Spanish acronym) reported today.

Cuba studied a total of 17,477 samples for surveillance during the day, resulting in 549 positive results. The country accumulates 10, 558,968 samples taken and 953,183 positive.

As part of Cuba's participation at the United Nations Climate Summit COP26, Elba Rosa Perez, minister of science, technology and environment, presented on Monday at the University of Glasgow, Scotland, a documentary on the implementation of the Tarea Vida (Task Life) in the Caribbean nation.

The Finlay Institute of Vaccines published on Monday the final results of the Phase III trial of the Cuban anti-COVID-19 Soberana 02 vaccine, with promising results.

Cuban scientist Tania Crombet, current director of clinical research at the Havana-based Molecular Immunology Center, was elected member of The World Academy of Sciences—TWAS--, an institution aim at advancing sciences in developing nations.

Cuba studied a total of 20,856 samples to detect COVID 19, with 633 positive results. The country accumulates 10, 541,921 samples taken and 952,634 positive.

Cuba maintains a significant reduction in the number of autochthonous cases during the current week, reporting today 625 new cases of SARS-CoV-2 coronavirus, the cause of COVID-19.

The Roswell Park Institute, in the United States, announced the start of a new clinical trial with the Cuban vaccine CIMAvax-EGF, developed by the Center for Molecular Immunology (CIM), to prevent lung cancer.

72.9 % of the vaccine-eligible population in Cuba has already completed the anti-COVID-19 scheme with the national immunogens Soberana 02, Soberana Plus and Abdala.

The phase II clinical study for COVID-19 convalescents, with the vaccine candidate Mambisa and the vaccine Abdala, began the inclusion of patients at the Hermanos Ameijeiras Hospital.